Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377391 | 0.87 | MAPT (0.45) | MAPTKMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL6249532 | 0.86 | MAPT (0.47) | MAPTKMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL5385804 | 0.86 | KCNH3 (0.52) | MAPTKMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL7087516 | 0.81 | NFKB1 (0.44) | SOS1MAPTKMT2ALMNAMAPK1 | |
| SCHEMBL5376637 | 0.81 | METAP2 (0.46) | MAPTKMT2AALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL5376587 | 0.81 | MEN1 (0.41) | MAPTKMT2AALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL5385724 | 0.81 | KCNH3 (0.54) | MAPTKMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL6396556 | 0.80 | EGFR (0.53) | MAPTKMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL5377014 | 0.80 | NFKB1 (0.40) | MAPTKMT2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5379154 | 0.80 | METAP2 (0.50) | MAPTKMT2ALMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | claimed |
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | MARINO JOSEPH P | 2005-10-06 | — | — | US | claimed |
| EP-1576092-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003083068-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | MARINO JOSEPH P | 2005-10-06 | — | — | US | disclosed |
| EP-1576092-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2003083068-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | SOS1 3711/4885MAPT 2319/4885KMT2A 1092/4885 |
| US-20050222212-A1 | Non-peptide, reversible inhibitors of bacterial methionine aminopeptidases, e.g., 3-anilino-5-(thiophen-2-ylmethylthio)-1,2,4-triazole | METAP1, ANPEP, METAP2 | SOS1 2409/4885MAPT 3195/4885KMT2A 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.